Crossmark

Regional seropositivity for Borrelia burgdorferi and associated risk factors: findings from the Rhineland Study, Germany

Published Online: 2022-07-04

Authors

Coors, Annabell

Hassenstein, Max J.

Krause, Gérard

Kerrinnes, Tobias

Harries, Manuela

Breteler, Monique M. B.

Castell, Stefanie
Funding

Funding for this research was provided by:

Initiative and Networking Fund of the Helmholtz Association (RA-285/19)

Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft
License Information

Text and Data Mining valid from 2022-07-04

Version of Record valid from 2022-07-04
More Information

Article History

Received: 21 February 2022

Accepted: 28 May 2022

First Online: 4 July 2022

Declarations

:

: The ethics committee of the Medical Faculty of the University of Bonn reviewed and approved the study protocol for the Rhineland Study. The study followed the recommendations of the International Council for Harmonisation Good Clinical Practice standards (ICH-GCP). All participants provided written informed consent.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current